EHSI Acquires Stem Cell Biotech Firm Celulas Genetica

HOUSTON--(BUSINESS WIRE)-- Emerging Healthcare Solutions, Inc. (Pink Sheets:EHSI) today announced its acquisition of Celulas Genetica, a biotechnology firm based in Panama.

EHSI initially signed a profit participation agreement with the company in March. Headquartered in Panama City, Panama, Celulas Genetica is a Central American leader in stem-cell technology acquisition and development. Earlier this week, the company purchased a license to develop and market the revolutionary Rutherford Procedure, a groundbreaking organ regeneration treatment designed to use proton-beam technology to destroy diseased organ tissue for regeneration using adult stem cells.

“Celulas Genetica’s license to develop and market the Rutherford Procedure was our main motivator to complete this acquisition,” said EHSI President and CEO Cindy Morrissey. “We intend to test this innovative procedure thoroughly and develop it into a viable treatment for deadly illnesses such as liver disease. The worldwide demand for stem-cell therapies of this kind is extraordinary.”

For more information on Celulas Genetica, visit http://www.TheStemCellGroup.com.

Celulas Genetica will be only the latest outpost in Emerging Healthcare Solutions’ global footprint. In addition to its Houston headquarters, the company also maintains business offices in Frankfurt, Germany and Warsaw, Poland.

“Much of the top stem-cell research being conducted today takes place outside the United States,” Morrissey said. “To be an industry leader in this field, you have to be international, and we fully intend to fund and produce industry-leading innovations.”

EHSI invests in technology developed to compete in the stem-cell research industry alongside Celgene Corporation (NASDAQ:CELG), Gilead Sciences Inc. (NASDAQ:GILD), Life Technologies Corporation (NASDAQ:LIFE) and Illumina Inc. (NASDAQ:ILMN).

About Emerging Healthcare Solutions, Inc.

Emerging Healthcare Solutions, Inc. invests in and participates in the profits of emerging breakthrough medical technologies. The Company believes the secret of leveraging future value for its shareholders is the proper timing of its investment in promising new medical technologies. EHSI aims to capture future profits of promising new medical technologies by investing in these technologies at the inflection point of product development. We believe this model will deliver long-term positive results for our investors.

For more information, please visit http://www.EmergingHealthcareSolutionsInc.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.



CONTACT:

Emerging Healthcare Solutions, Inc.
Cindy Morrissey, 713-821-1486
President and CEO

KEYWORDS:   United States  North America  Central America  Panama  Texas

INDUSTRY KEYWORDS:   Stem Cells  Technology  Software  Health  Biotechnology  Medical Devices

MEDIA:

Suggested Articles

PureTech Health has decamped from Cambridge to Boston’s Seaport neighborhood as a step toward growing the company and ramping up its pipeline.

In this week's EuroBiotech Report, Sanofi cuts staff in R&D rejig, AstraZeneca bets on Korea and uniQure weighs buyout bids.

In our EuroBiotech roundup this week, BioNTech and Genmab start cancer trial, Oncopeptides posts cancer data and F-star hires CFO.